Marea Therapeutics
Clinical trials sponsored by Marea Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug MAR002 aims to tame acromegaly in early trial Results expected Aug 2027 (estimated)
-
New drug MAR002 aims to tame acromegaly in early trial
Disease control Recruiting nowThis Phase 2 trial tests a new drug called MAR002 in 72 adults with acromegaly, a condition caused by a pituitary tumor that leads to too much growth hormone. Participants will receive either MAR002 or a placebo as injections under the skin. The study will check if the drug is sa…
Phase 2 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MAR001 aims to tackle stubborn high triglycerides
Disease control Recruiting nowThis Phase 2b study tests whether the experimental drug MAR001 can lower high triglycerides and remnant cholesterol in adults. About 216 participants will receive either MAR001 or a placebo by injection. The main goal is to see if MAR001 reduces triglyceride levels more than plac…
Phase 2 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug MAR002 takes first step toward treating acromegaly
Disease control Recruiting nowThis Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.
Phase 1 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot aims to tame After-Meal fat spikes in High-Risk patients
Disease control Recruiting nowThis Phase 2 study tests whether the drug MAR001 can lower blood fat levels after a meal in adults with high triglycerides. Thirty participants will receive either MAR001 or a placebo injection. The main goal is to see if MAR001 reduces the rise in triglycerides and remnant chole…
Phase 2 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC